Detalles de la búsqueda
1.
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Ann Oncol
; 27(4): 654-60, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26802160
2.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Ann Oncol
; 26(9): 1923-1929, 2015 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26091808
3.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Ann Oncol
; 27(6): 1180, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26945010
4.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Ann Oncol
; 26(12): 2505, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26489442
5.
Splenic sequela of babesiosis.
QJM
; 113(8): 577-578, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31670802
Resultados
1 -
5
de 5
1
Próxima >
>>